menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Ontario Regional Dinner Meeting On Polycythemia Vera: Identifying Potential Patients for the VERIFY Trial

A Phase 3 Study of Rusfertide (PTG-300) In Patients With Polycythemia Vera 

Live Meeting
Information
October 24, 2023
06:30 PM - 08:00 PM EDT
David Duncan House, 125 Moatfield Dr. North York, Ontario ON M3B 3L6, Canada
ReachMD Healthcare Image
Details
Presenters
Comments
  • Overview

    Polycythemia Vera (PV) is a chronic and rare condition that significantly increases the risk of thrombotic events and cardiovascular complications. Despite existing therapies, many patients do not achieve optimal disease control. Each regional dinner meeting will explore the possibilities of enrolling patients in the VERIFY study, a clinical trial that is investigating the potential of rusfertide as a treatment option for this vulnerable patient population.

    Join us for an informative evening near you for a discussion with a VERIFY investigator, where we will delve into the intricacies of PV and review the eligibility criteria for patients interested in participating in this study.

  • Target Audience

    This activity has been designed to meet the educational needs of health care professionals involved in the management of patients with polycythemia vera.

  • What is the VERIFY study?

    The purpose of the VERIFY clinical trial is to evaluate how safe and effective rusfertide is in maintaining hematocrit control and improving PV symptoms. Rusfertide, also known as PTG-300, is an investigational drug designed to slow the release of iron into the blood. This study is evaluating the ability for rusfertide to control the number of red blood cells (hematocrit level) to reduce, delay or eliminate phlebotomy, and improve patients’ quality of life. To learn more visit www.polycythemiavera-clinicaltrial.com

  • Commercial Support

     

    Supported by Protagonist Therapeutics

  • Fee Statement

    This activity is FREE for all participants.

Facebook Comments

Details
Presenters
Comments
Recommended
  • Overview

    Polycythemia Vera (PV) is a chronic and rare condition that significantly increases the risk of thrombotic events and cardiovascular complications. Despite existing therapies, many patients do not achieve optimal disease control. Each regional dinner meeting will explore the possibilities of enrolling patients in the VERIFY study, a clinical trial that is investigating the potential of rusfertide as a treatment option for this vulnerable patient population.

    Join us for an informative evening near you for a discussion with a VERIFY investigator, where we will delve into the intricacies of PV and review the eligibility criteria for patients interested in participating in this study.

  • Target Audience

    This activity has been designed to meet the educational needs of health care professionals involved in the management of patients with polycythemia vera.

  • What is the VERIFY study?

    The purpose of the VERIFY clinical trial is to evaluate how safe and effective rusfertide is in maintaining hematocrit control and improving PV symptoms. Rusfertide, also known as PTG-300, is an investigational drug designed to slow the release of iron into the blood. This study is evaluating the ability for rusfertide to control the number of red blood cells (hematocrit level) to reduce, delay or eliminate phlebotomy, and improve patients’ quality of life. To learn more visit www.polycythemiavera-clinicaltrial.com

  • Commercial Support

     

    Supported by Protagonist Therapeutics

  • Fee Statement

    This activity is FREE for all participants.

Facebook Comments

Schedule15 Jun 2024